Drug Resistant Melanoma May Be Vulnerable to Inhibitors of Serine Synthesis

NRAS-driven melanomas frequently develop resistance to MAPK/extracellular signal–regulated kinase kinase inhibitors (MEKis), which limits their therapeutic utility. Nguyen et al. (2020) show that MEKi-resistant cells upregulate phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in serine synthesis. Suppression of PHGDH rendered cells sensitive to MEKis, suggesting that PHGDH may be a therapeutic target for melanoma.

Source link

Related posts

Selective Expansion of Double Negative iNKT Cells Inhibits the Development of Atopic Dermatitis in Vα14 TCR Transgenic NC/Nga Mice by Increasing Memory-Type CD8+ T and Regulatory CD4+ T Cells


West Palm Beach, FL dermatologist, offers Dysport injections for combating the signs of aging


Top 10 products of 2019


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy